NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition
Go back to NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition| (NASDAQ: NTHI) | Delayed: 3.78 +0.10 (2.72%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.68 | 52 Week High | $ | |||
| Open | $3.82 | 52 Week Low | $ | |||
| Day High | $4.00 | P/E | N/A | |||
| Day Low | $3.69 | EPS | $ | |||
| Volume | 290,506 | |||||
